Corporate Report

Login or register to view PDF.
US Cardiology 2004;2004:1(1):1-4



Heart disease, heart attacks and chronic heart failure combined are the most fatal and expensive worldwide health issue. Over US$200 billion worldwide (BMS, 2004) is spent annually and, despite all the advances and breakthroughs, chronic heart failure resulting from a serious myocardial infarction ultimately remains a death sentence. The American Heart Association (AHA) reports that over five million Americans are currently living with heart failure and an extra 550,000 new cases are diagnosed each year.

While some available treatments can provide support for patients experiencing acute heart failure, many patients do not respond to the treatments. There is growing evidence to suggest that earlier deployment of mechanical circulatory support is a critical determinant of success. As a result, the potential to salvage the heart muscle and promote recovery holds significant promise.

Cardiologists and cardiac surgeons search for novel treatment solutions to reduce the high incidence of morbidity and mortality for profound heart failure patients through:

  • earlier institution of circulatory support;
  • ventricular offloading coupled with end-organ reperfusion; and
  • minimally invasive approaches




CardiacAssist, Inc., (CAI) was co-founded in 1996 by John Marous and Dr George Magovern, Sr, to innovate such novel treatment solutions utilizing revolutionary, reliable and profitable ventricular assist technology. The companyÔÇÖs flagship product, the TandemHeart┬« PTVA┬« System, is a unique proprietary solution for the hemodynamic needs of patients for circulatory support for use by both cardiologists and cardiac surgeons. These specialists have historically used intra-aortic balloon pumps (IABP) to provide some improved coronary artery perfusion, but the TandemHeart PTVA System provides true left ventricle off-loading of up to four liters per minute and eliminates gaps in cardiac care by offering critically ill patients new alternatives and treatment options not available through the IABP or other minimally invasive approaches.